What is doryx mpc?

See the DrugPatentWatch profile for doryx

What is Doryx MPC?

Doryx MPC (doxycycline hyclate delayed-release tablets) is an antibiotic medication used to treat various bacterial infections [1]. The MPC version is a type of tablet designed for use with a specific capsule-based delayed release technology that aims to improve the solubility and absorption of the active ingredient, allowing for more consistent blood levels.

When was Doryx MPC approved?

The FDA approved Doryx MPC in 2014 [2], expanding the existing Doryx line by offering a new formulation for adults and children with acne, rosacea, Lyme disease, anthrax, and more.

How does Doryx MPC work?

Doxycycline hyclate, the active ingredient in Doryx MPC, is a type of broad-spectrum antibiotic that works by inhibiting bacterial growth and multiplication. It is effective in treating various bacterial infections, including acne, rosacea, periodontitis, urinary tract infections, and more [3].


Key differences between Doryx MPC and other doxycycline products

According to various sources, including DrugPatentWatch.com [4], the main differences between Doryx MPC and other doxycycline formulations lie in their dosage form and release mechanisms. The MPC version is designed to provide sustained drug release and to be used without the need for a separate dosing capsule.


Please note: The availability and usage of Doryx MPC or any medication may vary depending on the region, country, or state.